Table 1 Patient characteristics.
Characteristics | Total (N = 1024) | Training group (N = 675) | Validation group (N = 349) | P value |
|---|---|---|---|---|
Age (year) | ||||
< 60 | 878(85.74%) | 582 (86.22%) | 296 (84.81%) | |
≥ 60 | 146(14.26%) | 93 (13.78%) | 53 (15.19%) | 0.532 |
Sex | ||||
Male | 890 (86.91%) | 585 (86.67%) | 305 (87.39%) | 0.304 |
Female | 134 (13.09%) | 90 (13.33%) | 44 (12.61%) | |
Histology | ||||
WHO I | 28 (2.73%) | 17 (2.52%) | 11 (3.15%) | 0.364 |
WHO II | 105 (10.25%) | 69 (10.22%) | 36 (10.31%) | |
WHO III | 877 (85.65%) | 579 (85.78%) | 298 (85.39%) | |
Other | 14 (1.37%) | 10 (1.48%) | 4 (1.15%) | |
T category | ||||
1 | 194 (18.95%) | 122 (18.08%) | 72 (20.63%) | 0.575 |
2 | 250 (24.41%) | 165 (24.44%) | 85 (24.36%) | |
3 | 320 (31.25%) | 223 (33.04%) | 97 (27.79%) | |
4 | 260 (25.39%) | 165 (24.44%) | 95 (27.22%) | |
N category | ||||
0 | 82 (8.01%) | 47 (6.96%) | 35 (10.03%) | 0.794 |
1 | 198 (19.34%) | 129 (19.11%) | 69 (19.77%) | |
2 | 579 (56.54%) | 385 (57.04%) | 194 (55.59%) | |
3 | 165 (16.11%) | 114 (16.89%) | 51 (14.61%) | |
Stage | ||||
I | 26 (2.54%) | 16 (2.37%) | 10 (2.87%) | 0.774 |
II | 73 (7.13%) | 50 (7.41%) | 23 (6.59%) | |
III | 535 (52.25%) | 352 (52.15%) | 183 (52.43%) | |
IV | 390 (38.08%) | 257 (38.07%) | 133 (38.11%) | |
WBC | ||||
< 6.3 (× 10^9/L) | 371 (36.2%) | 244 (36.1%) | 127 (36.4%) | 0.879 |
≥ 6.3 (× 10^9/L) | 653 (63.8%) | 431 (63.9%) | 222 (63.6%) | |
N | ||||
< 2.1 (× 10^9/L) | 24 (2.3%) | 18 (2.7%) | 6 (1.7%) | 0.057 |
≥ 2.1 (× 10^9/L) | 1000 (97.7%) | 657 (97.3%) | 343 (98.3%) | |
L | ||||
< 2.3 (× 10^9/L) | 11 (1.1%) | 6 (0.9%) | 5 (1.4%) | 0.11 |
≥ 2.3 (× 10^9/L) | 1013 (98.9%) | 669 (99.1%) | 344 (98.6%) | |
M | ||||
< 0.49 (× 10^9/L) | 437 (42.7%) | 300 (44.4%) | 137 (39.3%) | 0.051 |
≥ 0.49 (× 10^9/L) | 587 (57.3%) | 375 (55.6%) | 212 (60.7%) | |
PLT | ||||
< 136 (× 10^9/L) | 957 (93.5%) | 630 (93.3%) | 327 (93.7%) | 0.198 |
≥ 136 (× 10^9/L) | 67 (6.5%) | 45 (6.7%) | 22 (6.3%) | |
HB | ||||
< 111 (g/L) | 38 (3.7%) | 24 (3.6%) | 14 (4.0%) | 0.533 |
≥ 111 (g/L) | 986 (96.3%) | 651 (96.4%) | 335 (96.0%) | |
ALB | ||||
< 39.7 (g/L) | 295 (28.8%) | 195 (28.9%) | 100 (28.7%) | 0.875 |
≥ 39.7 (g/L) | 729 (71.2%) | 480 (71.1%) | 249 (71.3%) | |
NLR | ||||
< 2.21 | 580 (56.6%) | 387 (57.3%) | 193 (55.3%) | 0.242 |
≥ 2.21 | 444 (43.4%) | 288 (42.7%) | 156 (44.7%) | |
PLR | ||||
< 226.15 | 896 (87.5%) | 595 (88.%1) | 301 (86.2%) | 0.084 |
≥ 226.15 | 128 (12.5%) | 80 (11.9%) | 48 (13.8%) | |
SII | ||||
< 1040 | 942 (92.0%) | 621 (92.0%) | 321 (92.0%) | 0.98 |
≥ 1040 | 82 (8.0%) | 54 (8.0%) | 28 (8.0%) | |
SIRI | ||||
< 1.2 | 647 (63.2%) | 426 (63.1%) | 221 (63.3%) | 0.068 |
≥ 1.2 | 377 (36.8%) | 249 (36.9%) | 128 (36.7%) | |
BMI | ||||
< 21.7 | 409 (39.9%) | 266 (39.4%) | 143 (41.0%) | 0.346 |
≥ 21.7 | 615 (60.1%) | 409 (60.6%) | 206 (59.0%) | |
PNI | ||||
< 56.9 | 919 (89.7%) | 616 (91.3%) | 303 (86.8%) | 0.666 |
≥ 56.9 | 105 (10.3%) | 59 (8.7%) | 46 (13.2%) | |
NRI | ||||
< 105.3 | 909 (88.8%) | 587 (87.0%) | 322 (92.3%) | 0.456 |
≥ 105.3 | 115 (11.2%) | 88 (13.0%) | 27 (7.7%) | |
PAR | ||||
< 3.58 | 956 (93.4%) | 632 (93.6%) | 324 (92.8%) | 0.336 |
≥ 3.58 | 68 (6.6%) | 43 (6.4%) | 25 (7.2%) | |